SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the Suzhou Industrial Park, marking a significant expansion of its presence in China. The company will invest RMB 3 billion in a new project for its Suzhou plant, which is anticipated to be operational by 2028.
This investment will fund the construction of new factory facilities and the localized production and manufacturing of key products within Roche’s diagnostic reagent and instrument equipment production and R&D base in Suzhou. The move is set to strengthen Roche’s commitment to the Chinese market and enhance its capabilities to serve local healthcare needs.
Roche Diagnostics has a history of strategic investments in Suzhou, having established its Asia Pacific production base in the city in 2015. The company further solidified its presence with the launch of the Asia Pacific R&D center in 2018. In 2020, Roche invested in a system reagent manufacturing base, followed by the introduction of PCR sample preservation kits and pathology laboratory platform reagent projects in 2021. The establishment of the Asia Pacific instrument production base in 2023 has been a testament to Roche’s continuous efforts to improve its industrial chain in China and expand its localized product offerings.
The latest investment is expected to further localize Roche’s production and R&D operations, enabling the company to better meet the growing demand for advanced diagnostic solutions in the Chinese market and reinforce its position as a leading player in the global healthcare industry. -Fineline Info & Tech
